Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study-Reference-Cited by-同舟云学术

Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study

Published:2016-06 Issue:6 Volume:48 Page:601-607
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Peyrin-Biroulet Laurent,Van Assche Gert,Sturm Andreas,Gisbert Javier P.,Gaya Daniel R.,Bokemeyer Bern,Mantzaris Gerassimos J.,Armuzzi Alessandro,Sebastian Shaji,Lara Nuria,Lynam Mark,Rojas-Farreras Sonia,Fan Tao,Ding Qian,Black Christopher M.,Kachroo Sumesh

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference20 articles.

1. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences;Loftus;Gastroenterology,2004

2. Economics of the use of biologics in the treatment of inflammatory bowel disease;Cohen;Gastroenterology Clinics of North America,2006

3. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL);Vavricka;Inflammatory Bowel Diseases,2012

4. Patients’ perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis;Casellas;Journal of Crohn's and Colitis,2014

5. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey;Schreiber;BMC Gastroenterology,2012

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Percepción del impacto del tratamiento biológico endovenoso sobre el ámbito laboral y personal en pacientes con enfermedad inflamatoria intestinal;Gastroenterología y Hepatología;2024-05

2. Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis;Global and Regional Health Technology Assessment;2024-03-07

3. Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy;AboutOpen;2024-03-02

4. Self‐reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web‐based platform;United European Gastroenterology Journal;2023-06-27

5. Nothing Compares to U-padacitinib;American Journal of Gastroenterology;2023-05-25